Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 19/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | NPM1 | P06748 | 13/20 | 0.67 |
| ▸ | INSR | P06213 | 11/20 | 0.67 |
| ▸ | JAK2 | O60674 | 2/20 | 0.65 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16267816 | 1.00 | ALK (1.00) | ALKCYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL18270276 | 1.00 | ALK (1.00) | ALKCYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL520641 | 1.00 | ALK (1.00) | ALKCYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL519782 | 1.00 | ALK (1.00) | ALKCYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL16267916 | 1.00 | ALK (1.00) | ALKCYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL16276764 | 1.00 | ALK (1.00) | ALKCYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL520654 | 0.94 | ALK (0.89) | ALKCYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL2483880 | 0.94 | ALK (0.89) | ALKCYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL17577023 | 0.93 | ALK (0.87) | ALKCYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL16276767 | 0.92 | ALK (0.85) | ALKCYP3A4CYP2C9CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3004111-A1 | PYRROLOTRIAZINES AS ALK INHIBITORS | Cephalon, Inc. (US) | 2016-04-13 | — | — | EP | claimed |
| WO-2014193932-A1 | PYRROLOTRIAZINES AS ALK INHIBITORS | CEPHALON, INC. (US) | 2014-12-04 | — | — | WO | claimed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | claimed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | claimed |
| US-20160347756-A1 | PYRROLOTRIAZINES AS ALK INHIBITORS | CEPHALON, INC. | 2016-12-01 | — | — | US | disclosed |
| US-9440984-B2 | Pyrrolotriazines as ALK inhibitors | CEPHALON, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| EP-3004111-A1 | PYRROLOTRIAZINES AS ALK INHIBITORS | Cephalon, Inc. (US) | 2016-04-13 | — | — | EP | disclosed |
| US-20160068535-A1 | PYRROLOTRIAZINES AS ALK INHIBITORS | CEPHALON, INC. | 2016-03-10 | — | — | US | disclosed |
| WO-2014193932-A1 | PYRROLOTRIAZINES AS ALK INHIBITORS | CEPHALON, INC. (US) | 2014-12-04 | — | — | WO | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068535-A1 | PYRROLOTRIAZINES AS ALK INHIBITORS | ALK, ACVR1, AGTR1 | ALK 1/4885CYP3A4 2894/4885CYP2C9 3684/4885 |
| US-20160347756-A1 | PYRROLOTRIAZINES AS ALK INHIBITORS | ALK, ACVR1, AGTR1 | ALK 1/4885CYP3A4 2894/4885CYP2C9 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.